Back to Search
Start Over
Data on administration of cyclosporine, nicorandil, metoprolol on reperfusion related outcomes in ST-segment Elevation Myocardial Infarction treated with percutaneous coronary intervention
- Source :
- Data in Brief, Vol 14, Iss C, Pp 197-205 (2017)
- Publication Year :
- 2017
- Publisher :
- Elsevier, 2017.
-
Abstract
- Mortality and morbidity in patients with ST elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) are still high [1]. A huge amount of the myocardial damage is related to the mitochondrial events happening during reperfusion [2]. Several drugs directly and indirectly targeting mitochondria have been administered at the time of the PCI and their effect on fatal (all-cause mortality, cardiovascular (CV) death) and non fatal (hospital readmission for heart failure (HF)) outcomes have been tested showing conflicting results [3–16]. Data from 15 trials have been pooled with the aim to analyze the effect of drug administration versus placebo on outcome [17]. Subgroup analysis are here analyzed: considering only randomized clinical trial (RCT) on cyclosporine or nicorandil [3–5,9–11], excluding a trial on metoprolol [12] and comparing trial with follow-up length
Details
- Language :
- English
- ISSN :
- 23523409
- Volume :
- 14
- Issue :
- C
- Database :
- Directory of Open Access Journals
- Journal :
- Data in Brief
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.1abee9d424643c6bff5982ea5b367bc
- Document Type :
- article
- Full Text :
- https://doi.org/10.1016/j.dib.2017.07.033